CD274 and melanoma: Second, when immunotherapy (ipilimumab) plus PD‐1/PD‐L1 or combination PD‐1/PD‐L1 inhibitors used in melanoma, the rate of grade 3‐5AEs showed AEs increased significantly, which is also consistent with previous results.57, 58